Pricing Sign in

VRCA

Verrica Pharmaceuticals Inc.distress 7/10 · high distress / dilution risk

$5.51-3%today-39% from 52w high

verrica.com76 employeesFounded 2013West Chester, PABiotechnology

Lead: Common Warts (Verruca Vulgaris)

Revenue

pre-revenue

Liquidity

$21M

Runway

1.5 yrs

Shares 1y

+82%

Price & events

-28.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

-3.3%

1D

-0.9%

1W

-2.5%

1M

-15.1%

3M

-25.7%

6M

-21.8%

1Y

-92.7%

2Y

-94.8%

5Y

-95.4%

All

Overview

Market Cap: $94.66M
Enterprise Value: $74.06M
Volume: 2.35K
52 Week Range: $3.28 – $9.10
Total Shares: 17.18M
Float Shares: 7.90M
Short %: 3.68%
% Held by Insiders: 48.75%
% Held by Institutions: 27.87%
RVOL: 0.06x
Beta: 1.48

Pipeline stages · 3 programs

VP-102

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-06

VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-08

Cantharidin

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-04-30

Pipeline · 3 trials · 3 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-06 Estimated 50% readout ~2027-08-15	Phase 3	VP-102	Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts	—	recruiting
2027-08 Estimated 50% readout ~2027-10-15	Phase 3	VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)	Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts	—	not yet recruiting
2028-04-30 Estimated 50% readout ~2028-07-14	Phase 3	Cantharidin	Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts	—	recruiting

Catalyst news & presentations · 9

2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
later this yearconferencedata presentationsecondaryVP-315 · Comprehensive overview with genomic and immune response data to be presented at a scientific conference.SEC 8-K
end of 2025readoutYCANTH (TO-208) · Expected approval decision in Japan for molluscum contagiosumSEC 8-K
fourth quarter of 2025trial initiationsecondaryPhase 3VP-102 (YCANTH) · First patient dosing in global Phase 3 program for common warts.SEC 8-K
end of 2025regulatory submissionFiled (NDA/BLA)YCANTH (TO-208) · Japanese regulatory decision expected; $10M milestone payable upon approval.SEC 8-K
2025-07-01partnershipVP-102 (YCANTH) · Received $8 million milestone from Torii for initiating global Phase 3 program in common warts.SEC 8-K
first half of 2025trial initiationsecondaryPhase 3YCANTH (VP-102) · Initiation of global pivotal Phase 3 clinical trial for common wartsSEC 8-K
2025-06-27partnershipYCANTH (VP-102) · Amendment with Torii: $8M milestone for Phase 3 initiation (received July 2025), $10M milestone for Japan approval (expected end 2025)SEC 8-K
2024-05-15partnershipYCANTH (VP-102) · Amended collaboration with Torii to equally fund global Phase 3 common warts trial and $8M milestone on first patient dosed in JapanSEC 8-K

Approved drugs (1)

YCANTHCANTHARIDIN2023 · Prescription

Capital structure — dilution & financing

Shares out: 17,178,786 · 1 offerings/1y · 1 PIPEs

2025-12-23424B3offering
2025-12-23EFFECTshelf_effective
2025-12-15S-3shelf_registration
2025-11-248-Kprivate_placement
2025-07-018-Kmaterial_agreement
2025-06-128-Kmaterial_agreement
2025-03-25EFFECTshelf_effective

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

strong buy · target $16 (+182% upside) · 5 analysts

2025-12-18Brookline CapitalHold → Buy
2025-05-14NeedhamHold
2025-04-09NeedhamHold
2025-04-08HC Wainwright & Co.Neutral
2025-03-12NeedhamHold
2024-12-20NeedhamHold

Competitors — Common Warts (Verruca Vulgaris)

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.